021-51111890
购物车（）
sales@molnova.cn
AUNP-12 TFA (1353563-85-5 free base)
CAS No. ——
AUNP-12 TFA (1353563-85-5 free base) ( NP-12 TFA )
产品货号. M29774 CAS No. ——
AUNP-12 TFA (NP-12 TFA) is a polypeptide antagonist in the pd-1 signaling pathway, which has the same antagonistic effect on pd-l1 and pd-l2, and can protect the proliferation and effector function of lymphocytes.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AUNP-12 TFA (1353563-85-5 free base)
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述AUNP-12 TFA (NP-12 TFA) is a polypeptide antagonist in the pd-1 signaling pathway, which has the same antagonistic effect on pd-l1 and pd-l2, and can protect the proliferation and effector function of lymphocytes.
-
产品描述AUNP-12 TFA (NP-12 TFA) is a polypeptide antagonist in the pd-1 signaling pathway, which has the same antagonistic effect on pd-l1 and pd-l2, and can protect the proliferation and effector function of lymphocytes.(In Vitro):NP-12 TFA displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions . NP-12 TFA rescues the proliferation in the mouse splenocyte assay system with average EC50 values of 17 nM and 16.6 nM against rmPD-L1 and rmPD-L2 respectively . NP-12 TFA is also able to significantly rescue recombinant human PD-L1 and PD-L2 mediated inhibition of in vitro human PBMC proliferation, with average EC50 values of 63.3 nM and 44.1 nM against PD-L1 and PD-L2 respectively .
-
体外实验——
-
体内实验——
-
同义词NP-12 TFA
-
通路Others
-
靶点Other Targets
-
受体PD-1 sigling pathway
-
研究领域——
-
适应症——
化学信息
-
CAS Number——
-
分子量3375.63
-
分子式C144H227F3N40O50
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称Sequence:Ser-Asn-Thr-Ser-Glu-Ser-Phe-Lys(Ser-Asn-Thr-Ser-Glu-Ser-Phe)-Phe-Arg-Val-Thr-Gln -Leu-Ala-Pro-Lys-Ala-Gln-Ile-Lys-Glu-NH2
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
Sasikumar PG, et al. A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy. Mol Cancer Ther. 2019 Jun;18(6):1081-1091.
